# Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients

> **NCT02766348** · PHASE2 · UNKNOWN · sponsor: **Shenzhen Hornetcorn Bio-technology Company, LTD** · enrollment: 60 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** gemcitabine
- **BIOLOGICAL:** DC-CTL
- **DRUG:** cisplatinum

## Key facts

- **NCT ID:** NCT02766348
- **Lead sponsor:** Shenzhen Hornetcorn Bio-technology Company, LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02766348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02766348, "Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02766348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*